Zeta designs and develops tumor-specific biomarkers using cutting-edge technology to uniquely select the immunogens for our famed RAbMono™ (Rabbit Monoclonal) and MonoMAb™ (Monospecific monoclonal antibodies). Zeta’s MonoMAb™ and RAbMono™ Antibodies are produced through hybridoma and recombinant technologies.
Zeta offers over 375 individual primary antibodies of high-quality IVD certified for Pathology/IHC to select, including Mouse Monoclonals, Rabbit Monoclonals, and Rabbit Polyclonals. These antibodies are carefully chosen and developed to consistently produce staining on formalin-fixed paraffin-embedded tissue (FFPE) sections.
Our antibodies are carefully screened and rigorously tested to provide unparalleled consistency and reliability in immunohistochemical staining. Every antibody developed in-house goes through Design and Development processes as required by ISO 13485 and every lot undergoes QC testing for IHC on the FFPE tissue section for optimal quality.
Zeta is committed to satisfying your clinical needs through our customer-oriented philosophy and a dynamic approach to R&D activities. Zeta is focused only on a single application for these antibodies, IHC, to maximize over 50 years of our scientists’ combined experience and provide our clients with reliable and reproducible primary antibodies.